Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-03-07 Sale |
2024-03-08 5:31 pm |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
7,137 | $46.28 | $330,290 | 8,398 (Direct) |
View |
| 2022-08-31 Sale |
2022-09-02 4:27 pm |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
65,231 | $38.31 | $2,499,023 | 16,796 (Direct) |
View |
| 2022-03-04 Sale |
2022-03-08 7:35 pm |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
21,710 | $30.5 | $662,208 | 17,232 (Direct) |
View |
| 2021-05-28 Sale |
2021-06-01 4:11 pm |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
6,067 | $18.81 | $114,120 | 32,232 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-03-11 Option Award |
2024-03-12 6:35 pm |
N/A 2034-03-10 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
65,000 | $0 | 65,000 (Direct) |
View |
| 2024-03-07 Exercise |
2024-03-08 5:31 pm |
N/A 2024-03-11 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
8,641 | $0 | 8,398 (Direct) |
View |
| 2024-03-07 Tax Withholding |
2024-03-08 5:31 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
1,504 | $45.96 | 8,398 (Direct) |
View |
| 2024-03-07 Exercise |
2024-03-08 5:31 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
8,641 | $9.85 | 8,398 (Direct) |
View |
| 2023-12-29 Other |
2024-01-02 4:41 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
8,398 | $0 | 16,796 (Direct) |
View |
| 2023-03-10 Option Award |
2023-03-14 4:46 pm |
N/A 2033-03-09 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
75,000 | $0 | 75,000 (Direct) |
View |
| 2022-08-31 Exercise |
2022-09-02 4:27 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
55,000 | $4.75 | 16,796 (Direct) |
View |
| 2022-09-01 Tax Withholding |
2022-09-02 4:27 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
6,121 | $38.81 | 16,796 (Direct) |
View |
| 2022-08-31 Exercise |
2022-09-02 4:27 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
17,488 | $2.67 | 16,796 (Direct) |
View |
| 2022-08-31 Exercise |
2022-09-02 4:27 pm |
N/A 2022-12-31 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
72,488 | $0 | 16,796 (Direct) |
View |
| 2022-08-31 Tax Withholding |
2022-09-02 4:27 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
1,572 | $37.86 | 16,796 (Direct) |
View |
| 2022-03-10 Option Award |
2022-03-14 4:21 pm |
N/A 2032-03-09 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
75,000 | $0 | 75,000 (Direct) |
View |
| 2022-03-04 Exercise |
2022-03-08 7:35 pm |
N/A 2022-03-10 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
7,406 | $0 | 17,232 (Direct) |
View |
| 2022-03-04 Tax Withholding |
2022-03-08 7:35 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
696 | $31.42 | 17,232 (Direct) |
View |
| 2022-03-04 Exercise |
2022-03-08 7:35 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
7,406 | $3.67 | 17,232 (Direct) |
View |
| 2021-05-28 Exercise |
2021-06-01 4:11 pm |
N/A 2021-05-28 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
25,719 | $0 | 32,232 (Direct) |
View |
| 2021-05-28 Tax Withholding |
2021-06-01 4:11 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
4,216 | $18.91 | 32,232 (Direct) |
View |
| 2021-05-28 Exercise |
2021-06-01 4:11 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
13,374 | $3.85 | 32,232 (Direct) |
View |
| 2021-05-28 Exercise |
2021-06-01 4:11 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
12,345 | $3.76 | 32,232 (Direct) |
View |
| 2021-03-12 Option Award |
2021-03-15 4:43 pm |
N/A 2031-03-11 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
65,000 | $0 | 65,000 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-02 5:40 pm |
N/A 2020-06-02 |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
8,230 | $0 | 16,796 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-02 5:40 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
8,230 | $3.56 | 16,796 (Direct) |
View |
| 2020-06-01 Tax Withholding |
2020-06-02 5:40 pm |
N/A N/A |
Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation |
1,630 | $13.7 | 16,796 (Direct) |
View |